Your browser doesn't support javascript.
loading
Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439.
Shackleford, David M; Chiu, Francis C K; Katneni, Kasiram; Blundell, Scott; McLaren, Jenna; Wang, Xiaofang; Zhou, Lin; Sriraghavan, Kamaraj; Alker, André M; Hunziker, Daniel; Scheurer, Christian; Zhao, Qingjie; Dong, Yuxiang; Möhrle, Jörg J; Abla, Nada; Matile, Hugues; Wittlin, Sergio; Vennerstrom, Jonathan L; Charman, Susan A.
Afiliación
  • Shackleford DM; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Chiu FCK; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Katneni K; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Blundell S; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • McLaren J; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Wang X; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Zhou L; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Sriraghavan K; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Alker AM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
  • Hunziker D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
  • Scheurer C; Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland.
  • Zhao Q; University of Basel, CH-4003 Basel, Switzerland.
  • Dong Y; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Möhrle JJ; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Abla N; Medicines for Malaria Venture, 20 Route de Pré-Bois, CH-1215 Geneva 15, Switzerland.
  • Matile H; Medicines for Malaria Venture, 20 Route de Pré-Bois, CH-1215 Geneva 15, Switzerland.
  • Wittlin S; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
  • Vennerstrom JL; Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland.
  • Charman SA; University of Basel, CH-4003 Basel, Switzerland.
ACS Infect Dis ; 7(7): 1885-1893, 2021 07 09.
Article en En | MEDLINE | ID: mdl-34101429
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antimaláricos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: ACS Infect Dis Año: 2021 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antimaláricos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: ACS Infect Dis Año: 2021 Tipo del documento: Article País de afiliación: Australia